Is Drägerwerk KGaA (XTRA:DRW3) Undervalued Following Strong Q2 2026 Earnings?

Drägerwerk KGaA (XTRA:DRW3) drew fresh attention after reporting second quarter 2026 earnings, with sales of €847.31 million and net income of €29.52 million compared with the prior year’s figures.

See our latest analysis for Drägerwerk KGaA.

The strong second quarter numbers arrived after a period of sharp share price gains for Drägerwerk KGaA, with the stock closing at €109.4 and showing a 30.55% 1 month share price return and 59.94% year to date share price return, alongside a 165.19% 3 year total shareholder return that points to momentum building rather than fading.

If earnings strength has you looking beyond Drägerwerk KGaA, this could be a moment to scan for other healthcare technology opportunities using the 128 healthcare AI stocks

After such a sharp move, Drägerwerk KGaA now trades above analyst price targets yet still screens at a large intrinsic value discount. Is the market being too cautious, or is it simply pricing recent progress carefully?

Preferred P/E of 12x: Is it justified?

On a simple snapshot, Drägerwerk KGaA trades on a P/E of 12x, which looks low compared with peers and industry benchmarks given the recent share price strength.

The P/E ratio links what you pay today to the company’s earnings. For a medical and safety technology group like Drägerwerk KGaA, it is a common way to benchmark how the market is valuing current profits relative to other listed healthcare equipment companies.

According to the checks provided, Drägerwerk KGaA trades on a P/E of 12x compared with a peer average of 26x and a European Medical Equipment industry average of 27x. An estimated fair P/E is reported at 16.4x. This indicates that the market is assigning a materially lower earnings multiple than both the sector and the level suggested by the SWS fair ratio model, assuming sentiment moved closer to those reference points.

Explore the SWS fair ratio for Drägerwerk KGaA

Result: Price-to-Earnings of 12x (UNDERVALUED)

However, there are clear risks if Drägerwerk KGaA experiences pressure on healthcare and industrial spending, or if current valuation models overestimate its intrinsic discount.

Find out about the key risks to this Drägerwerk KGaA narrative.

Another view on Drägerwerk KGaA’s value

The P/E picture looks supportive, but the SWS DCF model paints a stronger story for Drägerwerk KGaA. With the share price at €109.4 and an estimated future cash flow value of €262.95, the stock currently appears heavily undervalued based on these inputs. That gap raises a clear question: which signal should investors focus on more?

Look into how the SWS DCF model arrives at its fair value.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Drägerwerk KGaA for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 257 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

Does this mix of signals around Drägerwerk KGaA leave you curious or cautious? Take a moment to weigh the data, consider both sides of the story, and see the 4 key rewards and 1 important warning sign

Looking for more investment ideas beyond Drägerwerk KGaA?

If Drägerwerk KGaA has sharpened your focus on pricing and quality, use this momentum to broaden your watchlist with other carefully filtered opportunities on Simply Wall St.

• Spot potential bargains early by scanning the 257 high quality undervalued stocks that combine attractive pricing with solid fundamentals.
• Strengthen your income stream by reviewing the 433 dividend fortresses that aim for higher yields with a focus on resilience.
• Prioritise resilience by checking the 304 resilient stocks with low risk scores that score well on financial stability and downside protection.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com